HDA UK Media And Political Bulletin – 12 May 2017
Media Summary
World Health Organization tries moving closer to creating a ‘fair pricing’ model
STAT, Ed Silverman, 11 May 2017
After consultation with drug makers, advocacy groups, and government agencies, World Health Organization officials say they are gradually moving closer to a framework for fair pricing of prescription medicines. The Fair Pricing Forum was hosted by the government of the Netherlands, and was attended by over 200 invited stakeholders. However, Marie-Paule Kieny, assistant director general for health systems and innovation at the WHO emphasised: “By fair pricing, we don’t mean low pricing”. The Forum concluded with a strong stance against value-based pricing, which was said not to have improved access to medicines around the world.
MHRA Inspectorate Organogram
MHRA Inspectorate Blog, Mark Birse, 11 May 2017
The MHRA Inspectorate Blog has been updated to provide access to the MHRA Inspectorate organogram. This follows the March 2017 GMP-GDP Consultative Committee meeting where it was raised that many members would find it beneficial to access it. The GMP-GDP Consultative Committee is an informal committee established to discuss matters relating to the manufacture and wholesale distribution of medicines for human use between the MHRA, other governmental departments, the devolved administrations and relevant trade associations.
Parliamentary Coverage
There is no Parliamentary Coverage.
Full Coverage
MHRA Inspectorate Organogram
MHRA Inspectorate Blog, Mark Birse, 11 May 2017
We have today updated the sidebar of the MHRA Inspectorate Blog to provide access to the MHRA Inspectorate organogram.
At the March 2017 GMP-GDP Consultative Committee meeting we took an action to publish the MHRA Inspectorate Organogram as many members stated they found it useful and wished to be able to access it.
The GMP and GDP Consultative Committee is an informal committee established to discuss matters relating to the manufacture and wholesale distribution of medicines for human use between:
the Medicines and Healthcare products Regulatory Agency (MHRA)
other governmental departments
the devolved administrations
relevant trade associations